PHARMING GRP SP. ADRS (PHG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PHARMING GRP SP. ADRS (PHG) has a cash flow conversion efficiency ratio of 0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€10.71 Million ≈ $12.52 Million USD) by net assets (€277.10 Million ≈ $323.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PHARMING GRP SP. ADRS - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how PHARMING GRP SP. ADRS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PHARMING GRP SP. ADRS (PHG) financial obligations for a breakdown of total debt and financial obligations.
PHARMING GRP SP. ADRS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PHARMING GRP SP. ADRS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beibu Gulf Tourism Corp Ltd
SHG:603869
|
0.033x |
|
Anshan Senyuan Road Bridge
SHE:300210
|
0.026x |
|
Atal SA
WAR:1AT
|
-0.098x |
|
HDC Holdings Co Ltd
KO:012630
|
-0.021x |
|
EuroTeleSites AG
F:7YF
|
N/A |
|
Zhejiang Henglin Chair Industry Co Ltd Class A
SHG:603661
|
0.057x |
|
Metallus, Inc
NYSE:MTUS
|
-0.039x |
|
People & Technology Inc
KQ:137400
|
0.023x |
Annual Cash Flow Conversion Efficiency for PHARMING GRP SP. ADRS (2021–2025)
The table below shows the annual cash flow conversion efficiency of PHARMING GRP SP. ADRS from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see PHG market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €277.10 Million ≈ $323.96 Million |
€54.71 Million ≈ $63.96 Million |
0.197x | +2531.41% |
| 2024-12-31 | €221.06 Million ≈ $258.44 Million |
€-1.79 Million ≈ $-2.10 Million |
-0.008x | +89.73% |
| 2023-12-31 | €218.78 Million ≈ $255.78 Million |
€-17.30 Million ≈ $-20.23 Million |
-0.079x | -172.06% |
| 2022-12-31 | €204.64 Million ≈ $239.24 Million |
€22.46 Million ≈ $26.26 Million |
0.110x | -44.05% |
| 2021-12-31 | €192.92 Million ≈ $225.54 Million |
€37.84 Million ≈ $44.24 Million |
0.196x | -- |
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more